Search - tctmd.com

Displaying 201 - 220 of 310

Sort: Relevancy | Date

News Daily News

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Todd Neale

March 22, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

Presentation SIF 2017

Best Practices: Evolut R

Presenter: Ramon Quesada

March 11, 2017

News Conference News CRT 2017

Lotus TAVR Device With Depth Guard Reduces Risk of Pacemaker Implantation

Michael O'Riordan

February 22, 2017

Presentation JIM 2017

CoreValve™ Evolut™ R Tavi System Intermediate Risk Indication

Presenter: Alberto Cremonesi

February 10, 2017

Presentation JIM 2017

Mitraclip Evolution: Where Do We Stand? The New Frontiers in Mitral Valve Repair and Replacement

Presenter: Fausto Castriota

February 10, 2017

News Daily News

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Michael O'Riordan

February 09, 2017

Presentation

Initial Experience of Second-Generation Self-Expandable TAVR System (Evolut R)

February 09, 2017

Presentation

Early Clinical Outcomes with Self-Expandable TAVR System (Evolut R) in Severe AS

Presenter: Jeffrey Popma

February 09, 2017

Presentation JIM 2017

“Evolution of TAVI: transfemoral outcomes using ACURATE neo”

Presenter: Corrado Tamburino

February 09, 2017

News Daily News

Clinical Outcomes With Subclavian TAVR as Good as With Transfemoral Access, Small Analysis Shows

Michael O'Riordan

January 26, 2017

News Features

The Prickly Problem of Permanent Pacing After TAVR: One Hospital Pitches a Protocol

Michael O'Riordan

January 24, 2017

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Shelley Wood

November 01, 2016

News Daily News

FDA Approves 34-mm TAVR Valve for Patients With Larger Anatomy

L.A. McKeown

October 27, 2016

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

某些患者 TAVR 后认知改善，但也有些下降，导致很难有统一指南

Shelley Wood

September 29, 2016

News Daily News

La Cognición Post-TAVR Mejora en Algunos Pacientes y Desciende en Otros y son Pocas las Señales Orientativas

Shelley Wood

September 29, 2016

Advertisement

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Best Practices: Evolut R

Lotus TAVR Device With Depth Guard Reduces Risk of Pacemaker Implantation

CoreValve™ Evolut™ R Tavi System Intermediate Risk Indication

Mitraclip Evolution: Where Do We Stand? The New Frontiers in Mitral Valve Repair and Replacement

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Initial Experience of Second-Generation Self-Expandable TAVR System (Evolut R)

Early Clinical Outcomes with Self-Expandable TAVR System (Evolut R) in Severe AS

“Evolution of TAVI: transfemoral outcomes using ACURATE neo”

Clinical Outcomes With Subclavian TAVR as Good as With Transfemoral Access, Small Analysis Shows

The Prickly Problem of Permanent Pacing After TAVR: One Hospital Pitches a Protocol

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

FDA Approves 34-mm TAVR Valve for Patients With Larger Anatomy

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

某些患者 TAVR 后认知改善，但也有些下降，导致很难有统一指南

La Cognición Post-TAVR Mejora en Algunos Pacientes y Desciende en Otros y son Pocas las Señales Orientativas

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content